Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
about
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerMultigene assays and molecular markers in breast cancer: systematic review of health economic analysesCost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancerCost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsA retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancerEconomic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Cost-utility analyses of drug therapies in breast cancer: a systematic review.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Issues surrounding the health economic evaluation of genomic technologies.Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.Is individualized medicine more cost-effective? A systematic review.Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification.Cost Effectiveness of Gene Expression Profile Testing in Community Practice.The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
P2860
Q26748855-27EC9D0F-0F43-46A0-9B37-A5E95CAD6C51Q26825362-26006B55-C3E2-4E3D-BD57-95C5D1299DC5Q28072203-3614FE5B-374C-4749-B252-BD8084C59FAEQ30252422-488C65CF-9CF7-4DF8-91AE-4E11EADE90C7Q30405851-B4D401CB-F7B3-4DE2-94FE-C9D5384ADFF3Q30543788-3B21FBB4-45DF-409B-9840-2CD7EBE54778Q30845285-CB11868C-DE90-4158-B122-F678DF21402CQ33766513-C72A9574-DB70-42E7-A150-5FF9DE349B61Q34171119-256BF133-FA2B-48AA-9AE2-11C1334E87ABQ34338152-7E8A4BFD-934F-46A3-8C2B-CA30ED735EE7Q34854883-9DD1887E-FC49-4CAC-9AD5-D1107E2192C9Q35008290-D57CB0F9-E5CD-4054-A8D0-721905E5A933Q35237375-B88BDB8C-4923-4A3F-8F0E-241DBE88E687Q35890606-B7B16A18-C3F6-4DDB-B7E2-0E2DA8C11830Q36116276-FCB5394D-9F1D-4CD9-BDC8-6C1DEFF6DA87Q36339076-0AC14C90-544E-4E52-A27A-295BA0683220Q36364504-9986CEE2-44FD-4E82-89CC-237EC40DBC09Q36424052-E15379F5-5C5B-4F3F-B73F-23AD2A02FB66Q36476471-2B469C4F-66E9-4500-B0B8-D662AAAEB498Q36997719-B673E7CC-8D98-4EBD-8944-BB83F828252EQ37151779-0AB1D0E3-C12C-4399-8EE7-A2ED55C228D7Q37541151-2D34BCC7-16FD-485C-9279-FF047DED5C62Q37659082-90CEFC00-EABB-4D01-906F-A944C8ABE269Q38048818-068DE8AD-A753-426A-87CC-4668779E37ECQ38081244-F658F155-2BCF-4655-86A3-940CD88FE3D3Q38191496-0186D442-ACB2-4CD6-B136-98E00732A512Q40124991-C82D497B-B99D-4182-AD9E-C68DD84FEE31Q40634876-E33C57A5-3ED0-4EA3-BDBE-6CFBA9D5D53EQ43790330-1F0CC787-A0E8-43DD-A512-7DC3329A34B8Q47198620-1EB897B6-5ECC-40A8-8CE9-DC9908BC94A4Q47835415-1E619B39-08E0-4022-B1C6-4D048D4081D5Q48318138-1CCC19A9-B9D6-48DC-960F-9DC987EF5BBBQ52586260-67CEDD2C-448F-4355-BE5E-D38A519221CA
P2860
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Economic evaluation of genomic ...... h node-positive breast cancer.
@ast
Economic evaluation of genomic ...... h node-positive breast cancer.
@en
Economic evaluation of genomic ...... h node-positive breast cancer.
@nl
type
label
Economic evaluation of genomic ...... h node-positive breast cancer.
@ast
Economic evaluation of genomic ...... h node-positive breast cancer.
@en
Economic evaluation of genomic ...... h node-positive breast cancer.
@nl
prefLabel
Economic evaluation of genomic ...... h node-positive breast cancer.
@ast
Economic evaluation of genomic ...... h node-positive breast cancer.
@en
Economic evaluation of genomic ...... h node-positive breast cancer.
@nl
P356
P1476
Economic evaluation of genomic ...... h node-positive breast cancer.
@en
P2093
Christopher McCabe
David Cameron
P356
10.1093/JNCI/DJR484
P407
P5530
P577
2011-12-02T00:00:00Z
P5875
P6179
1019885902